Kraig Biocraft Laboratories, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 16, 2026, reporting continued net losses and an accumulated deficit of $59,804,823.
Key Highlights
- Net loss for nine months: The company reported a net loss of $3,095,751 for the nine months ended September 30, 2026, compared to a net loss of $2,835,732 for the same period in 2025.
- Accumulated deficit: The accumulated deficit reached $59,804,823 as of September 30, 2026, up from $56,709,072 at December 31, 2025.
- Revenue and gross loss: Revenue for both the three and nine months ended September 30, 2026 was $3,000, against a cost of revenues of $4,320, resulting in a gross loss of $1,320.
- Cash position: Cash and cash equivalents stood at $2,783,802 at September 30, 2026, compared to $1,790,236 at December 31, 2025.
- Shares outstanding: As of November 16, 2026, there were 1,122,984,957 shares of Class A common stock outstanding, with 0 shares of Class B common stock and 3 shares of preferred stock outstanding.
- Stockholders' deficit: Total stockholders' deficit was $(7,502,437) at September 30, 2026, compared to $(7,998,958) at December 31, 2025.
Kraig Biocraft's Financial Position and Operating Results Through September 2026
Kraig Biocraft Laboratories, Inc. (OTC:KBLB), a Wyoming-incorporated biotechnology company headquartered in Ann Arbor, Michigan, filed its quarterly report covering the period ended September 30, 2026. According to the filing, the company generates revenue in connection with its research and development activities and reported its first nominal revenue of $3,000 for the three and nine months ended September 30, 2026, a figure that did not appear in the comparable 2025 periods. Cost of revenues of $4,320 exceeded that amount, producing a gross loss of $1,320 for both periods reported.
The filing disclosed total operating expenses of $2,662,884 for the nine months ended September 30, 2026, compared to $2,652,125 in the prior-year period. Research and development expenses increased to $263,354 for the nine-month period, up from $97,007 in the corresponding 2025 period, according to the condensed consolidated statements of operations. Officer salaries of $580,924 and general and administrative expenses of $1,622,190 were also recorded for the nine months ended September 30, 2026. Interest expense for the nine-month period was $453,217, and the company reported interest income of $55,891 from its cash holdings.
The balance sheet as of September 30, 2026 showed total assets of $3,737,549, including an investment in gold bullions carried at a fair value of $460,038 against a cost of $241,120. Total liabilities were $11,239,986, with accounts payable and accrued expenses to related parties of $8,982,176 representing a substantial portion. During the nine months ended September 30, 2026, the company issued 25,364,093 shares of common stock for proceeds of $2,772,547 and issued 5,000,000 shares for services valued at $400,000, according to the statement of changes in stockholders' deficit.
What Was Disclosed
Kraig Biocraft Laboratories filed its quarterly report for the period ended September 30, 2026, disclosing a nine-month net loss of $3,095,751, an accumulated deficit of $59,804,823, nominal revenue of $3,000, and a total stockholders' deficit of $7,502,437.





Please wait processing your request...